ABSTRACT Viruses manipulate the complex interferon and interferon-stimulated gene (ISG) system in different ways. We have previously shown that HIV inhibits type I and III interferons in its key target cells but directly stimulates a subset of Ͼ20 ISGs in macrophages and dendritic cells, many of which are antiviral. Here, we examine the mechanism of induction of ISGs and show this occurs in two phases. The first phase was transient (0 to 24 h postinfection [hpi]), induced mainly by extracellular vesicles and one of its component proteins, HSP90␣, contained within the HIV inoculum. The second, dominant, and persistent phase (Ͼ48 hpi) was induced via newly transcribed HIV RNA and sensed via RIGI, as shown by the reduction in ISG expression after the knockdown of the RIGI adaptor, MAVS, by small interfering RNA (siRNA) and the inhibition of both the initiation and elongation of HIV transcription by short hairpin RNA (shRNA) transcriptional silencing. We further define the induction pathway, showing sequential HIV RNA stimulation via Tat, RIGI, MAVS, IRF1, and IRF7, also identified by siRNA knockdown. IRF1 also plays a key role in the first phase. We also show that the ISGs IFIT1 to -3 inhibit HIV production, measured as extracellular infectious virus. All induced antiviral ISGs probably lead to restriction of HIV replication in macrophages, contributing to a persistent, noncytopathic infection, while the inhibition of interferon facilitates spread to adjacent cells. Both may influence the size of macrophage HIV reservoirs in vivo. Elucidating the mechanisms of ISG induction may help in devising immunotherapeutic strategies to limit the size of these reservoirs.
Viperin attenuated HIV replication and show that IFIT1, -2, and -3 also attenuate HIV infection.
RESULTS

Induction of ISGs in HIV-infected MDMs occurs in two distinct phases, as reflected by antiretroviral treatment.
Previously, we showed that HIV infection of monocyte-derived macrophages (MDMs) and monocyte-derived DCs (MDDCs) blocked IFN induction by inhibiting TBK1 phosphorylation and subsequent IRF3 activation yet still stimulated the expression of 25 ISGs (6, 8, 20) . To investigate at which stage of the HIV replication cycle these ISGs were induced, MDMs were mock treated or infected with an HIV stock that was not depleted of EVs (EV ϩ HIV) in the presence or absence of inhibitors of reverse transcription (zidovudine [AZT]), integration (raltegravir [RAL] ), or protease activity resulting in virion maturation (ritonavir [RIT] ). In the absence of inhibitors, HIV infection increased from 22% Ϯ 5% of P24 ϩ cells (the baseline of input HIV) on day 1 postinfection (p.i.) to 52% Ϯ 12% (de novo viral expression) on day 9 p.i., while treatment with AZT and RAL decreased the number of P24 ϩ cells to baseline levels, indicating inhibition of HIV replication on days 3, 6, and 9 p.i. (Fig. 1A) . In RIT-treated cultures, we detected a constant level of P24 ϩ cells at all time points p.i., indicating that there was no inhibition of HIV P24 production in initially infected cells. In addition, there was no spread of infection, as no infectious extracellular virions were detected in the supernatants of RIT-treated cultures (data not shown). The induction of the ISGs Viperin, IFIT1, IFIT2, and IFIT3, previously shown to be the most upregulated ISGs in response to HIV infection of MDMs (6), was not inhibited by AZT, RAL, or RIT treatment 24 hpi. However, on days 3, 6, and 9 p.i., the induction of these ISGs was almost completely inhibited by AZT and RAL, while RIT treatment showed only a 2-or 4-fold decrease in ISG expression (Viperin and IFIT1 to -3) on days 6 and 9 p.i., respectively, compared to HIV infection in the absence of RIT (Fig. 1B to E) . We also assessed the quantity and kinetics of ISG induction using a primary R5 strain (NB2). The pattern of ISG induction by NB2 at 1, 3, 6, and 9 days p.i. (Fig. 1F ) was similar to that of the laboratory-adapted HIV BaL , although with higher levels of stimulation (60-fold, or 2 6 , compared to 16-to 32-fold, or 2 4 to 2 5 , for HIV BaL ), despite similar low multiplicities of infection (MOI).
We concluded that ISG induction occurs in 2 phases: an initial, minor phase that is transient and induced early upon HIV infection in response to incoming virions or any cellular or viral components present within the HIV inoculum (since ISG expression was detected up to 24 hpi with all inhibitors) and a second, major phase occurring late (3 days p.i.), which persists and is induced after viral integration, suggesting newly synthesized viral mRNAs or possibly downstream viral proteins may be the stimuli. This is consistent with the kinetics of production of de novo-spliced/unspliced RNA in macrophages.
Extracellular vesicles contained within the HIV BaL stock induce first-phase ISG expression. EVs, previously named microvesicles, are released in large numbers from infected T cells accompanying HIV virions, and we have recently reported that EVs derived from activated SupT1 or primary T cells, as well as their purified components (HSP90␣ and HSP90␤), modulate DC functions (21) . We therefore compared the ability of the EV ϩ HIV inoculum with that of a virus stock that had been depleted of EVs (EV Ϫ HIV) to determine if virions or EVs are responsible for the first, minor phase of ISG induction. As shown in Fig. 2A , EV ϩ HIV triggered an early increase in both IRF1 (2 to 24 hpi) and IFN-␤ (2 to 4 hpi), followed by other ISGs (4 to 24 hpi), which was significantly greater than that with EV Ϫ HIV (Fig. 2B) . The low-level spike in IFN-␤ was abruptly terminated after 4 hpi.
To confirm that EVs were responsible, rather than other components of the HIV inoculum, we next treated MDMs either with purified EVs alone (Fig. 2C ) or with HSP90␤ (Fig. 2D) . Both EV and HSP90␤ treatments led to low-level upregulation of IRF1 and IFN-␤ gene expression at 1 and 4 h posttreatment, followed by induction of other ISGs at 4 h. The ISG induction by EVs was inhibited by the knockdown of IRF1, but not Myd88
(the adaptor for all TLRs except TLR3) or TRIF (the adaptor for TLR4 and TLR3) (Fig. 3A to C), as shown for two representative ISGs, Viperin and IFIT1 ( Fig. 3D and E) , suggesting that EVs do not interact with any TLRs. Similar reductions in ISG levels were observed when IRF1 was knocked down after HSP90␤ treatment ( Fig. 3F and G) . Poly(I·C), a synthetic dsRNA known to interact with TLR3 (which uses TRIF as its adaptor protein), was used as a positive control. Knockdown of TRIF, but not MyD88, significantly reduced Seven-day-old MDMs were treated with either the reverse transcriptase inhibitor AZT, the integrase inhibitor RAL, or the protease inhibitor RIT; 50 M each drug was added 24 h prior to, during, and after EV ϩ HIV infection at 1.5 g of P24/10 6 cells (MOI ϭ 0.1). Mock infections were performed using medium only. (A) HIV infection was assessed by intracellular P24 flow cytometry on days 1, 2, 3, 6, and 9 p.i. The data show mean percentages of P24-positive cells (Ϯ standard errors of the mean [SEM]; n ϭ 3) relative to mock infections. (B to E) Viperin and IFIT1, -2, and -3 mRNA expression was examined on days 1, 2, 3, 6, and 9 p.i. in mock-treated or HIV-infected MDMs in the presence or absence of AZT, RAL, or RIT. The data are shown as the mean log 2 -fold change (FC) in mRNA expression (ϮSEM; n ϭ 3) compared to mock treatment as quantified by qPCR. All the data were normalized to GAPDH (glyceraldehyde-3-phosphate dehydrogenase). (F) Data are shown as the mean log 2 -fold change in mRNA expression of Viperin and IFT1, -2, and -3 after treatment of MDMs with HIV NB2 (R5 primary strain; MOI ϭ 0.1) on days 1 (d1), 3, 6, and 9 p.i. compared to mock treatment (n ϭ 3; **, P Ͻ 0.01).
the ISG expression of IFIT2 and Viperin at 8 h and 10 h post-poly(I·C) treatment ( Fig. 3H  and I ). Therefore, we conclude that the first-phase induction is not predominantly due to HIV binding, as EV Ϫ HIV did not induce significant upregulation of IFN-␤ and IRF1 gene expression by 4 h, but rather, it was due to the EV component of the HIV inoculum. Therefore, EVs are the main drivers of the minor first-phase ISG induction, which occurs via IRF1.
Newly transcribed HIV mRNA is the key signal for the induction of secondphase ISG expression. To distinguish whether HIV single-stranded RNA (ssRNA) or residual cDNA (or possibly downstream newly translated viral proteins) in the cytoplasm stimulated second-phase ISG expression via the RNA sensor RIGI or the DNA sensor cGAS (22) , and possibly IFI16 (23), we knocked down MAVS (the RIGI adaptor) and STING (the cGAS/IFI16 adaptor) 3 days prior to HIV inoculation. STING knockdown (70% Ϯ 15%) ( Fig. 4A and B ) had no effect on ISG induction (Fig. 4E to H) . Matched MAVS knockdown (65% Ϯ 7%) ( Fig. 4C and D ) had no effect on the induction of the top four induced ISGs (Viperin and IFIT1 to -3) in the first phase (day 1 p.i.). However, it significantly reduced the second phase of their induction by a peak of 6-fold for Viperin, 10-fold for IFIT1, 2-fold for IFIT2, and 4-fold for IFIT3 on days 3 and 6 p.i. (Fig. 4E to H) . Overall, these reductions of 60 to 85% correlated with the degree of MAVS knockdown, indicating that the newly transcribed HIV RNA sensed by RIGI and then MAVS was the key stimulus for this major phase of ISG induction. To further assess the roles of MAVS in ISG induction and HIV infection, we measured HIV production in cultures that were pretreated with either MAVS small interfering RNA (siRNA) or nontargeting (NT) siRNA prior to their infection. As shown in Fig. 4I , there was a significant increase (P Ͻ 0.03) in extracellular virus production, as measured by the number of infected TZM-bl cells on days 3 and 6 p.i., following MAVS knockdown, implying that a reduction in ISG expression due to MAVS knockdown increases HIV production.
To further confirm that the mRNA is the key stimulus for the major phase of ISG induction, we inhibited transcription of spliced and unspliced HIV RNA from the cDNA provirus using transcriptional gene silencing, as no drug inhibitors are currently available to block de novo transcription of the integrated HIV genome. shRNA specific to a sequence within the NF-B motifs in the U3 region of the HIV provirus (shPromA) and scrambled controls (shPromA-Scr) were delivered by vesicular stomatitis virus G protein (VSV-G)-pseudotyped lentiviral vectors expressing enhanced green fluorescent protein (eGFP) prior to HIV infection of MDMs, as recently reported (24) . After transfecting either the specific shPromA-BaL or the control shPromA-Scr in parallel, 20% Ϯ 3% of MDMs were transduced and expressed eGFP (Fig. 5A ). HIV infection measured by intracellular P24 antigen (Ag) expression was markedly reduced in the eGFP ϩ cells transduced with shPromA-BaL (2.1% Ϯ 0.5%) compared to eGFP ϩ cells transduced with shPromA-Scr (9% Ϯ 1.2%).
We then sorted the 4 different cell populations identified in MDMs transfected with shPromA-BaL (Fig. 5A , middle) to assess ISG induction. ISG expression was inhibited to baseline levels in eGFP ϩ P24 Ϫ cells and was markedly reduced in the eGFP ϩ P24 ϩ cells compared to eGFP Ϫ P24 ϩ cells (Fig. 5B ). There was no ISG expression in eGFP Ϫ P24 Ϫ All the data were normalized to GAPDH. (C) MDMs were mock treated or transfected 3 days prior to HIV infection with 50 nM either Tat or nontargeting siRNA using Lipofectamine RNAiMax. RNA was extracted on days 3 and 6 p.i., and ISG expression was quantified by qPCR. The mRNA expression (ϮSEM; n ϭ 3) of IRF1 and IRF7, IFIT1 to -3, and Viperin in mock treatment and following Tat-specific or NT siRNA treatment is shown. All the data were normalized to GAPDH. *, P Ͻ 0.05; **, P Ͻ 0.01. cells, and there were no off-target effects upon the transfection of shPromA-BaL in MDMs, as no IFN-␤ was detected upon transduction of these constructs alone, as shown in Fig. 5B and as previously reported (24) .
In addition, the HIV trans-activating (Tat) protein was knocked down to inhibit HIV RNA transcriptional elongation. Tat gene knockdown (80% Ϯ 8%) (data not shown) did not affect IRF1 gene expression, but on day 3 p.i., it significantly downregulated IFIT1 and Viperin (Fig. 5C ). On day 6 p.i., IRF7, IFIT1, IFIT2, IFIT3, and Viperin were also significantly downregulated, and this was particularly marked for IRF7, Viperin, and IFIT1 (up to 5-fold). In summary, the de novo-transcribed HIV mRNAs were the major pathogen-associated molecular patterns (PAMPs) for ISG induction, as shown by knocking down MAVS and Tat and by using an shRNA that blocks transcriptional activity of HIV.
IRF1 and IRF7 drive ISG induction in MDMs. IRF1 upregulation was associated with the first phase of ISG induction ( Fig. 3D and F) , and IRF1 is known to bind to the promoter region of the ISGs induced by HIV (3, 25) . As IRF7 binds to promoter motifs similar to those IRF1 binds to, we next assessed whether IRF1 and IRF7 play a role in the second phase of ISG induction.
We first examined IRF1 and IRF7 gene expression in both mock-and EV ϩ HIVinfected MDMs. IRF1 expression rose slightly by 6 days p.i., whereas IRF7 expression increased more markedly at the gene (Fig. 6A ) and protein ( Fig. 6B and C) levels. Both IRF1 (Fig. 6B ) and IRF7 (Fig. 6C ) expression levels were enriched in the HIV P24 ϩ MDMs. Then, we examined the effects of IRF1 and IRF7 gene knockdown on the expression of each other and on other ISGs. IRF1 knockdown (55% Ϯ 10%) (data not shown) significantly reduced IRF7 gene expression by 50% Ϯ 8% (Fig. 6F) , while IRF7 knockdown (84% Ϯ 12%) (data not shown) had no effect on IRF1 gene expression (Fig. 6G ). This suggests that IRF1 drives the expression of IRF7. Furthermore, individual knockdown of IRF1 significantly inhibited the induction of the ISGs Viperin and IFIT1 on day 1 p.i. by 57% Ϯ 18% and by 79% Ϯ 11% on days 3 and 6 p.i. (Fig. 6H) , while IRF7 knockdown inhibited ISG induction from day 3 p.i. onward by 75% Ϯ 15% (Fig. 6I ). This inhibition was even more marked and significant with concurrent knockdown of IRF1 and IRF7 (Fig. 6G) .
To confirm these observations, we assessed whether IRF7 could induce the same ISGs as IRF1 upon their transfection into human embryonic kidney 293T (HEK293T) cells (NIH AIDS Research and Reference Reagent Program). IRF1, IRF7, and phospho-IRF7 (pIRF7) (used as a positive control for ISG induction) were highly expressed in the transfected cells (Fig. 7A ). IRF1 induced IRF7 and the other ISGs, but not IFN-␣ or IFN-␤. As expected, pIRF7 was able to induce expression of IFN-␣ and IFN-␤, in addition to levels of ISG induction higher than the levels induced upon IRF1 transfection. However, pIRF7 did not induce IRF1 mRNA expression. Furthermore, unphosphorylated IRF7 did not induce IFN-␣, IFN-␤, or ISGs (Fig. 7B to D) .
In conclusion, we showed in HIV-infected macrophages that IRF7 was significantly more upregulated than IRF1 at the gene and protein levels and that they were both involved in the second phase of ISG induction. However, IRF1 effects appeared earlier than IRF7 effects, and the knockdown experiments suggested that IRF1 effects preceded those of IRF7. In HEK293T cells, IRF1 and pIRF7, but not IRF7, were able to drive the expression of HIV-stimulated ISGs.
Antiviral activity of IFITs. The IFIT1 to -3 family has been shown to have antiviral activity against vesicular stomatitis virus, Rift Valley fever virus, and influenza A virus (26) . However, the roles of its members in HIV infection have not been examined. Therefore, to determine whether IFIT1 to -3 exhibit an antiviral function against HIV-infected MDMs, we knocked down their expression individually by siRNA, followed by either mock or HIV treatment. siRNA treatment showed consistent reduction of 80% Ϯ 10% in IFIT mRNA gene expression (Fig. 8A) . This was also confirmed at the protein level, showing a significant reduction in IFIT1, -2, and -3 protein expression at days 6, 10, and 13 p.i. (Fig. 8B) . There was also a consistent and significant 1.5-Ϯ 0.4-fold increase (P Ͻ 0.05) in extracellular virus production on days 6, 10, and 13 p.i. (Fig. 8C) following individual knockdown of the IFITs, implying an antiviral role for the IFITs against HIV. However, no synergy of function or increase in extracellular virus production was observed with concurrent knockdown of the three IFITs, suggesting that they may work as a complex. In addition, this increase in virus production had no effect on cell viability and intercellular spread, as the HIV DNA copy numbers (data not shown) and the numbers of HIV P24 ϩ cells (Fig. 8D) were similar in the infected MDM cultures exposed to either the IFIT-specific or nontargeting siRNA.
To investigate whether complex formation by the three IFITs is required for antiviral activity against HIV, we first cotransfected either individual IFITs or Viperin, together with HIV BaL , into HEK293T cells. IFIT1, -2, -3 and Viperin were expressed to almost similar levels in HEK293T cells 3 days posttransfection (Fig. 8E) , and all the cultures showed equal numbers of HIV-transfected cells (Fig. 8F) . Compared to the equivalent ratio of the parental empty vector, individual IFIT1, -2, and -3 transfections did not reduce the number of infected TZM-bl cells (i.e., did not restrict extracellular-virus production) compared to the significant reduction induced upon Viperin transfection (Fig. 8G) . However, we were unable to properly test the antiviral effect upon transfection of IFIT1, 
FIG 8 IFIT1, IFIT2
, and IFIT3 knockdowns increased viral production from HIV-infected MDMs. (A) Seven-day-old MDMs were transfected with optimal siRNA concentrations to achieve maximum gene knockdown (10 nM IFIT1 siRNA, 20 nM IFIT2 siRNA, or 50 nM IFIT3 siRNA) using Lipofectamine (Invitrogen) 3 days prior to HIV infection. The MDMs were then either mock infected or exposed to HIV. The data represent the mean percentage reductions (ϮSEM; n ϭ 3) in IFIT1, -2, and -3 mRNA expression in MDMs transfected with gene-specific siRNA for IFIT1, -2, or -3, respectively, compared to nontargeting siRNA as quantified by qPCR on days 6, 10, and 13 p. -2, and -3 in combination, as there was a reduction in the expression levels of IFITs when two or more IFITs were cotransfected compared to single-IFIT transfection (data not shown).
DISCUSSION
The major focus of this study was the investigation of the mechanism of HIVmediated ISG induction in macrophages and the potential antiviral role of the IFIT family of proteins. Using antiretroviral drugs and HIV transcriptional silencing, we demonstrated that there are two phases of ISG induction: a first, minor phase (24 hpi) mediated by EVs that occurs prior to reverse transcription and a second, major phase (3 days p.i.) occurring after proviral integration and mediated by newly synthesized HIV mRNA (Fig. 9) . We then proceeded to show that the IFIT family of proteins has antiviral activity against HIV.
It has been shown that when transfected into cells, HIV RNA, HIV RNA-derived secondary-structure oligonucleotides, and cDNA can stimulate the induction of ISGs via RIGI/MAVS (for RNA) and cGAS/STING signaling (for cDNA) (27) (28) (29) (30) . We therefore knocked down MAVS and STING and found that this had no effect on the first phase of ISG induction. This is probably because first-phase ISG induction (4 to 24 hpi) occurs prior to viral replication, and only very small quantities of DNA escape into the cytoplasm during transport to the nuclear pore, and if they do so, they are eliminated by the DNase TREX (31) . Furthermore, there is increasing evidence that HIV capsids uncoat close to or at the nuclear pore after completion of reverse transcription (32), restricting exposure of genomic RNA and reverse-transcribed cDNA to cytoplasmic sensors. HIV may also recruit cyclophilin A or CPSF6 to the capsid to evade early innate immune recognition, although the exact mechanism remains controversial (33) (34) (35) . In addition, HIV cDNA in macrophages is synthesized later than 4 hpi, supporting our data showing that cDNA is not the PAMP inducing the first phase of ISG induction.
As we had previously shown that EVs activate DCs (21), we next turned our attention to EVs and showed that they were responsible for the first phase of ISG induction. We showed that an HIV stock containing EVs induced much higher levels of ISGs within 4 h than HIV depleted of EVs. Furthermore, both IRF1 and IFN-␤ were induced within 1 h, but IFN-␤ expression was transient and was gone by 6 h, suggesting that both were induced concurrently by EVs and that there was a secondary inhibition of IFN-␤, possibly via the intravirion HIV accessory protein Vpr (8) . The role of EVs was confirmed by demonstrating that MDMs treated with EVs isolated from activated SupT1 cells or with HSP90␤ (the major bioactive protein identified by proteomics in EVs from HIVinfected T cells [21] ) showed a similar early ISG induction pattern. As HSP90␤ has been reported to activate innate immune cells via TLR4 (36), we knocked down the two TLR4 adaptor molecules MyD88 and TRIF (37) to investigate whether the first phase of ISG induction occurred via TLR stimulation. However, neither MyD88 nor TRIF knockdown inhibited ISG induction, indicating that it occurs via an alternate pathway to TLR4 (or any other TLR). Furthermore, the NF-B pathway was not involved, as we detected concurrent phosphorylation of TBK1 and degradation of IB␣ with LPS, but not with HSP90␣, HSP90␤, EV, or EV ϩ HIV (data not shown). In addition, the knockdown of an endocytic receptor, CD91 (involved in the uptake of the heat shock proteins HSP70 and HSP96) (38) , in macrophages prior to EV or HSP90 treatment did not inhibit ISG induction by EVs (data not shown).
Therefore, the receptor for EV or HSP90␤ sensing needs further investigation. Even though we knocked down the key PRR adaptors (MAVS, STING, MyD88, and TRIF), the initial early spike in IRF1 and IFN-␤ was not affected, and it remains to be determined what mediates this very early EV-driven expression of the two genes. This will be investigated via systems biology approaches in the future.
Decalf et al. (39) recently published data complementary to this paper while it was in review. Several HIV strains induced early, transient, low levels of interferon and ISGs in macrophages prior to reverse transcription, in agreement with our results on first-phase ISG induction. However, the differences between HIV inocula with and without EVs was not examined.
The stimuli for the second phase of ISG induction operate after HIV cDNA integration, as shown by its marked inhibition by raltegravir, and before viral assembly and protein cleavage. Although MAVS knockdown had no effect on the early first phase of ISG induction, it did result in marked inhibition of the second phase. This strongly suggested that newly synthesized HIV RNA stimulated MAVS through RIGI to induce ISGs. We confirmed this by inhibiting both the initiation of HIV transcription, by silencing the viral promoter through shRNA targeting the NF-B binding site, and transcriptional elongation, by knocking down Tat. Both strategies markedly inhibited second-phase ISG induction (Ͼ48 h). These observations are consistent with the slower kinetics of unspliced and multiply spliced HIV mRNA production in macrophages detected from day 2 p.i. compared to 12 to 24 hpi in peripheral blood mononuclear cells (PBMCs) and 5 h after activation of ACH2 lymphoblastoid cells (40) .
Genomic HIV RNA is transcribed by a Tat/RNA polymerase II-dependent mechanism, and therefore, most, but not all, HIV RNA is capped and polyadenylated like host mRNAs (30, 41) . Normally, capped and polyadenylated RNA is not recognized by cellular RNA sensors, such as RIGI, which ordinarily recognizes double-stranded RNA and those with 5=triphosphate or diphosphate motifs (42) (43) (44) . However, many negative-stranded RNA viruses have "panhandles" containing blunt-ended 5=-triphosphate structures allowing RIGI detection (45) . For HIV, recent studies suggest that such newly transcribed HIV RNA can be differentiated from cellular RNAs by its high degree of secondary structure, including stem-loops or panhandles and other modifications. Therefore, HIV RNA can be differentially sensed by RIGI in the 5= and 3= untranslated regions, including the TAR stem-loop, which are likely to be recognized by RIGI and are probably more exposed in monomers than dimers (46, 47) . Solis et al. (30) showed that both purified monomeric and, to a lesser extent, dimeric genomic RNA (which is transcribed from cDNA and exposed in the cytoplasm prior to packaging) stimulated RIGI, but not MDA5, using knockdowns. Berg et al. (27) showed that highly structured RNA oligonucleotide homologs of the HIV genome were more stimulatory to RIGI than unstructured ones in both PBMCs and macrophages. The presence of 5=-triphosphorylated HIV RNAs in HIV-infected macrophages should be examined in the future.
Furthermore, recently, a retinoic acid derivative, acitretin, was reported to stimulate RIGI to reduce and eliminate HIV DNA levels in infected CEM T cells in vitro and in CD4 T cells from HIV ϩ ART-treated subjects ex vivo. However, only in HIV-infected cells did RIGI bind to MAVS and initiate downstream signaling. This work shows that RIGI does indeed recognize HIV RNAs in infected CD4 T cells in vivo and that it has antiviral activity (48) . Although it is possible that this ISG induction pathway could be modulated by HIV precursor proteins or regulatory proteins other than Tat, there is no precedent for such viral proteins to be the primary stimulus to RIGI or MAVS (29) .
We have previously shown in DCs that HIV induces the expression of IRF1 and -7 and that a subset of ISGs contain an IRF1/7 binding site. The HIV promoter region also contains the same IRF1/7 binding site, and we showed that mutating this sequence led to a reduction in infectivity (3) . In this study on macrophages, we found that IRF1 gene expression was upregulated as early as 1 hpi and that IRF7 gene expression was also upregulated at later time points. Furthermore, both IRF1 and -7 were upregulated at the protein level in all HIV-treated cells, with the highest expression detected in HIV P24 ϩ cells, with IRF7 levels Ͼ2-to 3-fold higher than those of IRF1. We therefore knocked down both these transcription factors and found that knocking down IRF1 significantly reduced IRF7 expression, but IRF7 knockdown had no effect on IRF1 expression. Thus, IRF1 drives the expression of IRF7. IRF1 knockdown reduced first-and second-phase ISG induction, whereas IRF7 knockdown inhibited only second-phase ISG induction.
As reported by the Aldovini laboratory, IFN-independent ISG expression in MDMs can be induced by Tat through either the regulation of mitogen-activated protein kinases or the upregulation of IRF7 transcription (49) . The latter supports our current study, since IRF7 expression is enriched in P24 ϩ MDMs, but cannot explain the effects upstream of IRF7 and particularly of MAVS knockdown. Together, our studies show that Tat may have two effects, via RNA elongation (i.e., newly transcribed RNA) and via direct upregulation of IRF7. Therefore, HIV infection of MDMs upregulates IRF1 and IRF7, probably to initiate its own replication (50) , but in so doing it also induces ISGs, which are dominant and downregulate the peak level of replication, probably contributing to the low-level noncytopathic HIV production by MDMs.
Finally, we assessed the antiviral activities of IFIT1, -2, and -3 and showed that individual knockdown of each inhibited extracellular HIV production. However, cotransfection of individual IFIT genes and HIV cDNA in HEK293T cells did not restrict extracellular viral production. This is probably because IFIT1 to -3 act cooperatively. Unfortunately, we were not able to transfect all three together due to inefficient transfection efficiency using three plasmids. We hypothesize that individual knockdown of IFIT1, -2, or -3 prevents complex formation. This would result in the loss of RNA sequestration by the complex or IFIT1 and -2 destabilizing the eIF3 ribosomal complex and thus increasing HIV production.
IFITs have been shown to inhibit viral replication by different mechanisms. The binding and sequestration of 5=-PPP RNA by the IFIT1, -2, and -3 complex (26) suppress viral replication of influenza virus, vesicular stomatitis virus, and Rift valley fever virus. However, for human papillomavirus, IFIT1 acts independently in restricting viral replication (51) . In the case of HIV infection, a recent study has shown that IFIT1 and IFIT3 were significantly upregulated in the PBMCs of elite controllers but not in HIV patients on ART with suppressed viremia (52) . The novel role of IFITs in inhibition of HIV production shown here requires further investigation to determine its exact mechanism and to compare it with other viruses.
A new mechanism of HIV-induced stimulation of the interferon/ISG pathway has recently been described and must be considered. HIV virions can transport cyclic GMP-AMP (cGAMP) from producer cells into target macrophages via membrane fusion, leading to STING stimulation and downstream interferon production. Exosomes also contained cGAMP but were unable to transfer it and stimulate via STING (53, 54) . However, there was marked cell type variation in cGAS and cGAMP levels and hence incorporation into cell-free virions, as clarified by Xu et al. (55) . Furthermore, unlike certain cell lines (HeLa and cGAS-transfected HEK293 cells), phytohemagglutinin (PHA)/ interleukin 2 (IL-2)-stimulated primary T cells do not incorporate cGAMP into virions. We also used such a cell-free T cell-derived HIV inoculum, so it is not surprising that our observations could not be explained by the cGAMP effect in either phase of ISG stimulation. In the first-phase, EVs, not HIV virions, were the dominant stimulus, and in the second phase, complete ablation of stimulation of all ISGs tested by the integrase inhibitor, raltegravir, was not compatible with either this mechanism or stimulation by cytosolic cDNA (preintegration) via cGAS and STING.
In conclusion, the interactions of HIV with the ISG-IFN system in macrophages is complex, involving both the virus itself, EVs, and several immune-evasive and counterimmune-evasive mechanisms, contributing to the characteristic low-level, noncytopathic, persistent infection. The importance of this ISG response to HIV is shown by its breadth and clear dependence on IRF1 promoter interactions. Therefore, these studies clarify the pathway of ISG induction in macrophages and now need to be extended to HIV infection of activated and resting T cells to consider how best to target potential interventions.
MATERIALS AND METHODS
Ethics statement. Whole blood used in this study to isolate monocytes was obtained through the Sydney Blood Bank after informed written consent and approval by the Sydney Blood Bank and the Research Ethics Committee at Westmead Hospital.
Generation of MDMs and HIV BaL virus. MDMs were generated from HIV-seronegative blood as described previously (56) . Titers of 6 ϫ 10 9 50% tissue culture infective doses (TCID 50 )/ml of either the primary strain, NB2 (as described in references 56 and 57), or the laboratory-adapted HIV BaL strain containing CD45 ϩ extracellular vesicles (EV ϩ HIV) or CD45 ϩ -depleted stocks (EV Ϫ HIV) were generated as described previously (21) . Endotoxin levels were below the detection limit (Limulus amebocyte lysate assay; Sigma) and were negative for tumor necrosis factor alpha (TNF-␣), IFN-␣, and IFN-␤ by enzymelinked immunosorbent assay (ELISA).
MDM treatment with EVs or recombinant proteins. EVs were generated in either primary T cells or SupT1.CCR5-CL.30 cells (human non-Hodgkin's T lymphocyte lymphoma; contributed by James Hoxie, University of Pennsylvania) as previously described (21) . They were then added to 7-day-old MDMs at 10 l/ml to match the EV concentration of EV ϩ HIV stocks, as determined by Western blot densitometry (21) . The recombinant protein HSP90␤ free of LPS (Abcam) was also matched to its concentration in EV ϩ HIV and used at the lowest effective concentration (5 nM) shown to enhance dendritic cell maturation (21) .
Gene knockdown of the PRR signaling pathways. For siRNA interference, synthetic IRF1, RIGI or DDX58, IRF7, MAVS, MyD88, STING, TRIF or TICAM1, IFIT1, IFIT2, IFIT3, Tat (58), and control nonsilencing (NT) siRNAs were purchased from Dharmacon, Waltham, MA. MDMs were washed twice with RPMI medium and then transfected with siRNA using Lipofectamine (Invitrogen) for 48 to 72 h prior to HIV, EV, or HSP90␤ exposure. The lowest concentrations of siRNA that displayed both the highest and most consistent reduction in mRNA gene expression (60 to 90% knockdown), as assessed by quantitative PCR (qPCR), or in protein levels, as assessed by Western blotting, were used. siRNA concentrations varied from 10 to 50 nM according to the targeted RNAs. Measurement of gene expression by qPCR was performed as described previously (59) using defined primers purchased from Sigma-Aldrich (Table 1) . Gene knockdown was maintained for up to 10 days after siRNA treatment, as shown at the gene level in Fig.  6A and at the protein level by Western blotting in Fig. 6B .
Transcriptional gene silencing (TGS) by lentiviral-shProm transduction. The vectors lentishPromA-BaL and lenti-Scramble (Scr) were constructed as previously described (60, 61) . To transduce MDMs with these lentiviral vectors, cells were plated in 96-well plates at 10 5 cells/well for 7 days, followed by inoculation with lenti-shPromA-BaL or lenti-shPromA-Scr (MOI ϭ 1.5) for 5 days. Transduction efficiency was then assessed by the expression of eGFP fluorescence by microscopy, followed by HIV BaL infection (MOI ϭ 0.1). Seven days p.i., MDM infectivity was assessed by intracellular P24 staining (KC57-RD1; Beckman Coulter, Fullerton, CA) and lentiviral transduction by eGFP on a FACS-Canto II flow cytometer (Becton Dickinson). FlowJo (Tree Star Inc., Ashland, OR) was used for data analysis, and cell sorting was then performed on a FACSVantage fluorescence-activated cell sorter (Becton Dickinson).
Cotransfection of full-length HIV, IFIT1 to -3, and Viperin cDNAs into HEK293T cells. The full-length infectious pWT/BaL proviral HIV DNA (NIH AIDS Research and Reference Reagent Program; contributed by Bryan R. Cullen) and either Viperin-pLNCX2, the control parental vector pLNCX2 (Promega), IFIT1-pCI neo, IFIT2-pCI neo, IFIT3-pCI neo, or the control parental vector pCI neo (Promega) were cotransfected at equal molar ratios into HEK293T cells using polyethylenimine (Sigma-Aldrich) in a 6-well plate as described previously (6) . At 72 h posttransfection, the supernatants were harvested, and infectious-virus release was measured as previously described (6) . The cells were also assessed for infection by measuring intracellular P24 expression by flow cytometry and for HIV DNA by measuring HIV long terminal repeat (LTR)-gag expression by qPCR as described previously (6, 62) .
Statistical analysis. For the gene expression value following HIV, EV, or HSP90␤ treatment, a Student t test (1 tail) was performed. After siRNA treatment, gene expression values were assessed for significance using a repeated-measure two-way analysis of variance (ANOVA), followed by Dunnett's post hoc correction compared with the time-matched NT siRNA. IFIT1  NM_001548  AGAACGGCTGCCTAATTTACAG  GCTCCAGACTATCCTTGACCTG  IFIT2  NM_001547  TGGTGGCAGAAGAGGAAGAT  GTAGGCTGCTCTAAGGAA  IFIT3  NM_001549  GCAGAGACACAGAGGGCAGT  TGGCATTTCAGCTGTGGA  IFN-␣ ␣  M54886.1  AATGGCCTTGACCTTTGCTT  CACAGAGCAGCTTGACTTGC  IFN-␤  NM_002176  GAAGCACAACAGGAGAGCAA  CGACACTGTTCGTGTTGTCA  GAPDH  NM_002046  GAGTCAACGGATTTGGTCGT  GACAAGTTCCCGTTCTCAG  Viperin  NM_080658  GGTGGGGTCTTTCATTCCCCCCTTTTTCTG  GATAGCGAGAATGTCCAAATACTCACC  IRF1  NM_002198  AAGTCCAGCCGAGATGCTAA  TAGCTGCTGTGGTCATCAGG  IRF7  NM_001572  AGCTGTGCTGGCGAGAAG  TGTGTGTGCCAGGAATGG  TRIF  NM_182919  AACAGAGCCAACACCTGGAC  GCTGAGTAGGCTGCGTTCA  STING  NM_198282  CGCCTCATTGCCTACCAG  GCTGCCCACAGTAACCTCTT  MAVS  NM_020746 TGCAGCAATGGTATCTGCAT AAATGATTCAGCGGGAGAAA a The IFN-␣ primer was designed to detect all subtypes of IFN-␣.
